출판 : MarketsandMarkets（마켓츠앤마켓츠）출판년월 : 2022년08월
세포 치료 기술(Cell Therapy Technologies) 시장 : 제품 (배지, 혈청 및 시약, 세포 배양 용기, 일회용 용품, 시스템 및 소프트웨어), 프로세스 (세포 처리), 세포 유형 (T 세포, 줄기 세포), 최종 사용자 (바이오파머, CMO), 지역별 – 2027년까지 세계 예측
Cell Therapy Technologies Market by Product (Media, Sera & Reagents, Cell Culture Vessels, Single Use Equipment, Systems & Software), Process (Cell Processing), Cell Type (T-cells, Stem Cells), End User (Biopharma, CMOs), Region – Global Forecast to 2027
| 페이지수 | 210 |
| 도표수 | 250 |
| 구성 | 영문조사보고서 |
| 가격 |
The cell therapy technologies market is projected to reach USD 8.0 Billion by 2027 from USD 4.0 Billion in 2022, at a CAGR of 14.6% during the forecast period. The growth can be attributed to the increasing public-private partnerships. Several government and private organizations have made significant investments to strengthen R&D in cell therapy leading to surge in cell therapy technologies demand, hence propelling market growth.
세포 치료 기술 시장은 예측 기간 동안 14.6%의 CAGR로 2022년 40억 달러에서 2027년 80억 달러에 이를 것으로 예상됩니다. 이러한 성장은 공공-민간 파트너십의 증가에 기인할 수 있습니다. 여러 정부 및 민간 조직이 세포 치료에 대한 R&D를 강화하기 위해 막대한 투자를 하여 세포 치료 기술 수요가 급증하여 시장 성장을 촉진하고 있습니다.
“The cell preservation and distribution and handling process segment accounted for the second largest share of the market in 2021”
Cell preservation and distribution is an essential and vital step in the cell scaling-up process. In addition, with the growth in the demand for cell-based medical products and therapies, the demand for reliable storage equipment to preserve finite cell lines and cells manufactured in excess is expected to increase. This factor is expected to drive the growth of this market segment.
“The CROs and CMOs accounted for the second largest share of the cell therapy technologies market in 2021”
To cater the large demand, pharmaceutical companies need to speed up clinical timelines, maintain business continuity, and free up resources for projects. This has increased outsourcing analytical tests to CROs and CMOs, thereby boosting the segment market growth.
Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Lonza Group (Switzerland), Sartorius AG (Germany), Terumo BCT (US), Becton, Dickinson and Company (US), Fresenius SE & Co. KGaA (Germany), Avantor, Inc. (US), Bio-Techne Corporation (US), Corning Incorporated (US), FUJIFILM Irvine Scientific (US), MaxCyte Inc. (US), Werum IT Solutions GmbH (Germany), RoosterBio Inc. (US), SIRION Biotech GmbH (Germany), TrakCel (UK), L7 Informatics, Inc. (US), Miltenyi Biotec GmbH (Germany), STEMCELL Technologies (Canada), GPI Iberia (Spain), MAK-SYSTEM (US), OrganaBio, LLC (US), IxCells Biotechnology (China), and Wilson Wolf Manufacturing Corporation (US), are some of the major players operating in the market.
“Asia Pacific: The fastest-growing region in the cell therapy technologies market”
The Asia Pacific market is expected to register the highest CAGR during the forecast period. Some of the major factors contributing to the growth of the Asia Pacific market are low-cost manufacturing advantage, increasing per capita income, and growing need to curb cancer. In addition, the growth of geriatric population is also fueling the cell therapy technologies market in the region.
The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 80% and Demand Side – 20%
• By Designation: Managers- 45%, CXOs and Director level – 30%, and Executives – 25%
• By Region: North America -20%, Europe -10%, Asia-Pacific -55%, RoW -15%
List of Companies Profiled in the Report:
• Thermo Fisher Scientific, Inc. (US)
• Merck KGaA (Germany)
• Danaher Corporation (US)
• Lonza Group (Switzerland)
• Sartorius AG (Germany)
• Terumo BCT (US)
• Becton, Dickinson and Company (US)
• Fresenius SE & Co. KGaA (Germany)
• Avantor, Inc. (US)
• Bio-Techne Corporation (US)
• Corning Incorporated (US)
• FUJIFILM Irvine Scientific (US)
• MaxCyte Inc. (US)
• Werum IT Solutions GmbH (Germany)
• RoosterBio Inc. (US)
• SIRION Biotech GmbH (Germany)
• TrakCel (UK)
• L7 Informatics, Inc. (US)
• Miltenyi Biotec GmbH (Germany)
• STEMCELL Technologies (Canada)
• GPI Iberia (Spain)
• MAK-SYSTEM (US), OrganaBio, LLC (US)
• IxCells Biotechnology (China)
• Wilson Wolf Manufacturing Corporation (US)
Research Coverage:
This report provides a detailed picture of the cell therapy technologies market. It aims at estimating the size and future growth potential of the market across different segments such as the product, process, cell type, end user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cell therapy technologies market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, challenges, trends, and opportunities.
목차
TABLE OF CONTENTS
1 INTRODUCTION (Page No. – 31)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 CELL THERAPY TECHNOLOGIES MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. – 35)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 BREAKDOWN OF PRIMARIES BY RESPONDENT, DESIGNATION, AND REGION: CELL THERAPY TECHNOLOGIES MARKET
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 4 CELL THERAPY TECHNOLOGIES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2021
FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2021
2.2.1 INSIGHTS FROM PRIMARY EXPERTS
FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
2.3 MARKET GROWTH RATE PROJECTIONS
FIGURE 7 CELL THERAPY TECHNOLOGIES MARKET (SUPPLY SIDE): CAGR PROJECTIONS
FIGURE 8 CELL THERAPY TECHNOLOGIES MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE FACTORS
2.4 DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ANALYSIS
3 EXECUTIVE SUMMARY (Page No. – 45)
FIGURE 10 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
FIGURE 11 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022 VS. 2027 (USD MILLION)
FIGURE 12 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 13 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF CELL THERAPY TECHNOLOGIES MARKET
4 PREMIUM INSIGHTS (Page No. – 49)
4.1 CELL THERAPY TECHNOLOGIES MARKET OVERVIEW
FIGURE 15 INCREASING GOVERNMENT INVESTMENTS IN CELL-BASED RESEARCH TO DRIVE MARKET GROWTH
4.2 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET SHARE, BY CELL TYPE AND COUNTRY (2021)
FIGURE 16 T CELLS SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2021
4.3 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY PRODUCT, 2022 VS. 2027
FIGURE 17 MEDIA, SERA, AND REAGENTS SEGMENT TO DOMINATE MARKET IN 2027
4.4 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY PROCESS, 2022
FIGURE 18 CELL PROCESSING SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2022
4.5 CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 19 ASIA PACIFIC COUNTRIES TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. – 52)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 20 CELL THERAPY TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing government investments in cell-based research
TABLE 1 NIH FUNDING FOR CELL-BASED RESEARCH, 2016–2019 (USD MILLION)
5.2.1.2 Rising incidence of chronic and infectious diseases
5.2.1.3 Large number of oncology-related cell therapy clinical trials
FIGURE 21 CANCER CELL THERAPY PIPELINE (MARCH 2019–MARCH 2020)
5.2.1.4 Increasing GMP certifications for cell therapy production facilities
TABLE 2 EXAMPLES OF MANUFACTURING CERTIFICATIONS AND APPROVALS FOR GMP
5.2.2 RESTRAINTS
5.2.2.1 High cost of cell-based research and low success rate
TABLE 3 COST OF CELL THERAPY EQUIPMENT
5.2.2.2 Dearth of skilled professionals
5.2.3 OPPORTUNITIES
5.2.3.1 Emergence of iPSCs as alternatives to ESCs
5.2.3.2 Increased focus on personalized medicine
5.2.3.3 Increasing public-private partnerships for development of cell therapies
5.2.3.4 Emerging Asian markets
5.2.4 CHALLENGES
5.2.4.1 Survival of small players and new entrants
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 22 REVENUE SHIFT AND NEW REVENUE POCKETS FOR CELL THERAPY TECHNOLOGIES PROVIDERS
5.4 INDICATIVE PRICING MODEL ANALYSIS
TABLE 4 PRICING ANALYSIS OF CELL THERAPY PRODUCTS
5.5 TECHNOLOGY ANALYSIS
5.6 VALUE CHAIN ANALYSIS
FIGURE 23 VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES CONTRIBUTE MAXIMUM VALUE
5.7 SUPPLY CHAIN ANALYSIS
FIGURE 24 CELL THERAPY TECHNOLOGIES MARKET: SUPPLY CHAIN ANALYSIS
5.8 ECOSYSTEM ANALYSIS OF CELL THERAPY TECHNOLOGIES MARKET
FIGURE 25 ECOSYSTEM ANALYSIS
TABLE 5 SUPPLY CHAIN ECOSYSTEM
5.9 KEY CONFERENCES AND EVENTS IN 2022–2023
TABLE 6 CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
5.10 REGULATORY ANALYSIS
5.10.1 NORTH AMERICA
TABLE 7 NORTH AMERICA: REGULATORY LANDSCAPE FOR CELL THERAPIES
5.10.2 EUROPE
TABLE 8 EUROPE: REGULATORY LANDSCAPE FOR CELL THERAPIES
5.10.3 ASIA PACIFIC
TABLE 9 ASIA PACIFIC: REGULATORY LANDSCAPE FOR CELL THERAPIES
5.10.4 REST OF THE WORLD
TABLE 10 REST OF THE WORLD: REGULATORY LANDSCAPE FOR CELL THERAPIES
5.11 PORTER’S FIVE FORCES ANALYSIS
TABLE 11 CELL THERAPY TECHNOLOGIES MARKET: PORTER’S FIVE FORCES ANALYSIS
5.11.1 THREAT OF NEW ENTRANTS
5.11.2 THREAT OF SUBSTITUTES
5.11.3 BARGAINING POWER OF SUPPLIERS
5.11.4 BARGAINING POWER OF BUYERS
5.11.5 DEGREE OF COMPETITION
5.12 PATENT ANALYSIS
FIGURE 26 PATENT APPLICATIONS FOR CELL THERAPY TECHNOLOGIES, JANUARY 2012–JULY 2022
TABLE 12 INDICATIVE LIST OF PATENTS IN CELL THERAPY TECHNOLOGIES MARKET
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 27 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF CELL THERAPY PRODUCTS
5.13.2 BUYING CRITERIA FOR CELL THERAPY PRODUCTS
FIGURE 28 KEY BUYING CRITERIA FOR END USERS
6 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT (Page No. – 73)
6.1 INTRODUCTION
TABLE 13 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
6.2 MEDIA, SERA, AND REAGENTS
6.2.1 MEDIA, SERA, AND REAGENTS ARE INTEGRAL PARTS OF CELL PROCESSING
TABLE 14 CELL THERAPY TECHNOLOGIES MARKET FOR MEDIA, SERA, AND REAGENTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 15 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR MEDIA, SERA, AND REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 16 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR MEDIA, SERA, AND REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 17 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR MEDIA, SERA, AND REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)
6.3 CELL ENGINEERING PRODUCTS
6.3.1 AVAILABILITY OF VARIOUS CELL ENGINEERING PRODUCTS SUPPORTS MARKET GROWTH
TABLE 18 CELL THERAPY TECHNOLOGIES MARKET FOR CELL ENGINEERING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 19 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ENGINEERING PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 20 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ENGINEERING PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 21 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ENGINEERING PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)
6.4 CELL CULTURE VESSELS
6.4.1 CELL CULTURE VESSELS ARE WIDELY USED FOR CELL GROWTH
TABLE 22 CELL THERAPY TECHNOLOGIES MARKET FOR CELL CULTURE VESSELS, BY REGION, 2020–2027 (USD MILLION)
TABLE 23 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CULTURE VESSELS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 24 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CULTURE VESSELS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 25 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CULTURE VESSELS, BY COUNTRY, 2020–2027 (USD MILLION)
6.5 EQUIPMENT
TABLE 26 CELL THERAPY TECHNOLOGIES MARKET FOR EQUIPMENT, BY REGION, 2020–2027 (USD MILLION)
TABLE 27 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 28 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 29 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 30 CELL THERAPY TECHNOLOGIES MARKET FOR EQUIPMENT, BY TYPE, 2020–2027 (USD MILLION)
6.5.1 CELL PROCESSING EQUIPMENT
6.5.1.1 Cell processing equipment segment dominates cell therapy equipment market
TABLE 31 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING EQUIPMENT, BY REGION, 2020–2027 (USD MILLION)
TABLE 32 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 33 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 34 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
6.5.2 SINGLE-USE EQUIPMENT
6.5.2.1 Benefits of single-use equipment have ensured end-user demand
TABLE 35 CELL THERAPY TECHNOLOGIES MARKET FOR SINGLE-USE EQUIPMENT, BY REGION, 2020–2027 (USD MILLION)
TABLE 36 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR SINGLE-USE EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 37 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR SINGLE-USE EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 38 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR SINGLE-USE EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
6.5.3 OTHER EQUIPMENT
TABLE 39 CELL THERAPY TECHNOLOGIES MARKET FOR OTHER EQUIPMENT, BY REGION, 2020–2027 (USD MILLION)
TABLE 40 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 41 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 42 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
6.6 SYSTEMS AND SOFTWARE
6.6.1 SYSTEMS AND SOFTWARE ARE USED TO MONITOR DIFFERENT STAGES OF CELL PROCESSING
TABLE 43 CELL THERAPY TECHNOLOGIES MARKET FOR SYSTEMS AND SOFTWARE, BY REGION, 2020–2027 (USD MILLION)
TABLE 44 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR SYSTEMS AND SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 45 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR SYSTEMS AND SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 46 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR SYSTEMS AND SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)
6.7 OTHER PRODUCTS
TABLE 47 CELL THERAPY TECHNOLOGIES MARKET FOR OTHER PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 48 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 49 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 50 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)
7 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS (Page No. – 90)
7.1 INTRODUCTION
TABLE 51 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
7.2 CELL PROCESSING
7.2.1 CELL PROCESSING MAKES WIDE USE OF CELL THERAPY INSTRUMENTS
TABLE 52 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY REGION, 2020–2027 (USD MILLION)
TABLE 53 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 54 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 55 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 CELL PRESERVATION, DISTRIBUTION, AND HANDLING
7.3.1 INCREASING DEMAND FOR CELL-BASED MEDICAL PRODUCTS AND THERAPIES TO DRIVE SEGMENT GROWTH
TABLE 56 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY REGION, 2020–2027 (USD MILLION)
TABLE 57 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 58 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 59 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2020–2027 (USD MILLION)
7.4 PROCESS MONITORING AND QUALITY CONTROL
7.4.1 PROCESS MONITORING IS ESSENTIAL TO ENSURE QUALITY AND ACCURACY OF CELL PROCESSING
TABLE 60 CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING AND QUALITY CONTROL, BY REGION, 2020–2027 (USD MILLION)
TABLE 61 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING AND QUALITY CONTROL, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 62 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING AND QUALITY CONTROL, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 63 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING AND QUALITY CONTROL, BY COUNTRY, 2020–2027 (USD MILLION)
8 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE (Page No. – 97)
8.1 INTRODUCTION
TABLE 64 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
8.2 T CELLS
8.2.1 RESEARCH CONDUCTED ON CAR T-CELL THERAPY TO ACCELERATE SEGMENT GROWTH
TABLE 65 CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY REGION, 2020–2027 (USD MILLION)
TABLE 66 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 67 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 68 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 STEM CELLS
8.3.1 INCREASING FUNDING FOR STEM CELL RESEARCH TO DRIVE SEGMENT GROWTH
TABLE 69 CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY REGION, 2020–2027 (USD MILLION)
TABLE 70 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 71 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 72 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2020–2027 (USD MILLION)
8.4 OTHER CELLS
TABLE 73 CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY REGION, 2020–2027 (USD MILLION)
TABLE 74 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 75 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 76 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2020–2027 (USD MILLION)
9 CELL THERAPY TECHNOLOGIES MARKET, BY END USER (Page No. – 104)
9.1 INTRODUCTION
TABLE 77 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2 BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
9.2.1 RISING NUMBER OF CELL THERAPY MANUFACTURING FACILITIES TO DRIVE SEGMENT GROWTH
TABLE 78 CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 79 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 80 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 81 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
9.3 CROS AND CMOS
9.3.1 RISING FOCUS ON OUTSOURCING TO DRIVE SEGMENT GROWTH
TABLE 82 CELL THERAPY TECHNOLOGIES MARKET FOR CROS AND CMOS, BY REGION, 2020–2027 (USD MILLION)
TABLE 83 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CROS AND CMOS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 84 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CROS AND CMOS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 85 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CROS AND CMOS, BY COUNTRY, 2020–2027 (USD MILLION)
9.4 RESEARCH INSTITUTES AND CELL BANKS
9.4.1 MARKET GROWTH IS SUPPORTED BY RISING RESEARCH ACTIVITY
TABLE 86 CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES AND CELL BANKS, BY REGION, 2020–2027 (USD MILLION)
TABLE 87 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES AND CELL BANKS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 88 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES AND CELL BANKS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 89 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES AND CELL BANKS, BY COUNTRY, 2020–2027 (USD MILLION)
10 CELL THERAPY TECHNOLOGIES MARKET, BY REGION (Page No. – 111)
10.1 INTRODUCTION
TABLE 90 CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2020–2027 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 29 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT
TABLE 91 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 92 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 93 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 94 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
TABLE 95 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 96 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2.1 US
10.2.1.1 Increasing R&D activities to support market growth
TABLE 97 US: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 98 US: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 99 US: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
TABLE 100 US: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 101 US: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Increasing government funding to drive adoption of cell therapy instruments
TABLE 102 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 103 CANADA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 104 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
TABLE 105 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 106 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3 EUROPE
TABLE 107 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 108 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 109 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 110 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
TABLE 111 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 112 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Germany holds largest share of European market
TABLE 113 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 114 GERMANY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 115 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
TABLE 116 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 117 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.2 UK
10.3.2.1 Favorable funding and investment scenario to drive market growth
TABLE 118 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 119 UK: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 120 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
TABLE 121 UK: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 122 UK: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Availability of government and private support to drive market growth
TABLE 123 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 124 FRANCE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 125 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
TABLE 126 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 127 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.4 ITALY
10.3.4.1 Initiatives favoring cell and gene therapy development to support market growth
TABLE 128 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 129 ITALY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 130 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
TABLE 131 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 132 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Increasing funding from private and public organizations to aid market growth
TABLE 133 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 134 SPAIN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 135 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
TABLE 136 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 137 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 138 ROE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 139 ROE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 140 ROE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
TABLE 141 ROE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 142 ROE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 30 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT
TABLE 143 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 144 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 145 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 146 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
TABLE 147 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 148 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.1 CHINA
10.4.1.1 Increasing cell therapy-based trials to support market growth
TABLE 149 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 150 CHINA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 151 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
TABLE 152 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 153 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Rising geriatric population and growing disease prevalence to drive market growth
TABLE 154 JAPAN: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
TABLE 155 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 156 JAPAN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 157 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
TABLE 158 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 159 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Favorable government regulations to support market growth
TABLE 160 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 161 INDIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 162 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
TABLE 163 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 164 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 165 ROAPAC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 166 ROAPAC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 167 ROAPAC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
TABLE 168 ROAPAC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 169 ROAPAC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 AVAILABILITY OF GRANTS FOR CELL-BASED RESEARCH TO DRIVE MARKET GROWTH
TABLE 170 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 171 LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 172 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
TABLE 173 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 174 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
10.6 MIDDLE EAST AND AFRICA
10.6.1 INCREASING R&D FUNDING FOR STEM CELL THERAPY TO DRIVE MARKET GROWTH
TABLE 175 MIDDLE EAST AND AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 176 MIDDLE EAST AND AFRICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 177 MIDDLE EAST AND AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
TABLE 178 MIDDLE EAST AND AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
TABLE 179 MIDDLE EAST AND AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. – 150)
11.1 INTRODUCTION
11.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
FIGURE 31 CELL THERAPY TECHNOLOGIES MARKET: STRATEGIES ADOPTED
11.3 MARKET SHARE ANALYSIS
FIGURE 32 CELL THERAPY TECHNOLOGIES MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2021)
TABLE 180 CELL THERAPY TECHNOLOGIES MARKET: DEGREE OF COMPETITION
11.4 REVENUE ANALYSIS
FIGURE 33 REVENUE ANALYSIS FOR KEY COMPANIES (2019–2021)
11.5 COMPANY EVALUATION MATRIX
FIGURE 34 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX, 2021
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.6 COMPANY EVALUATION MATRIX: START-UPS/SMES
FIGURE 35 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
11.6.5 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
TABLE 181 CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF KEY START-UPS/SMES
TABLE 182 CELL THERAPY TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES
11.7 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS
11.7.1 COMPANY FOOTPRINT (25 COMPANIES)
TABLE 183 COMPANY FOOTPRINT ANALYSIS: KEY PLAYERS
11.7.2 PRODUCT FOOTPRINT (25 COMPANIES)
TABLE 184 PRODUCT FOOTPRINT ANALYSIS: KEY PLAYERS
11.7.3 PROCESS FOOTPRINT (25 COMPANIES)
TABLE 185 PROCESS FOOTPRINT ANALYSIS: KEY PLAYERS
11.7.4 REGIONAL FOOTPRINT (25 COMPANIES)
TABLE 186 REGIONAL FOOTPRINT ANALYSIS: KEY PLAYERS
11.8 COMPETITIVE SCENARIO AND TRENDS
11.8.1 PRODUCT LAUNCHES
TABLE 187 CELL THERAPY TECHNOLOGIES MARKET: PRODUCT LAUNCHES (JANUARY 2019–JULY 2022)
11.8.2 DEALS
TABLE 188 CELL THERAPY TECHNOLOGIES MARKET: DEALS (JANUARY 2019–JULY 2022)
11.8.3 OTHER DEVELOPMENTS
TABLE 189 CELL THERAPY TECHNOLOGIES MARKET: OTHER DEVELOPMENTS (JANUARY 2019–JULY 2022)
12 COMPANY PROFILES (Page No. – 165)
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, MnM view, Key strengths/right to win, Strategic choices made, Weaknesses and competitive threats)*
12.1.1 THERMO FISHER SCIENTIFIC, INC.
TABLE 190 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 36 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
12.1.2 MERCK KGAA
TABLE 191 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 37 MERCK KGAA: COMPANY SNAPSHOT
12.1.3 DANAHER CORPORATION
TABLE 192 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 38 DANAHER CORPORATION: COMPANY SNAPSHOT
12.1.4 LONZA GROUP
TABLE 193 LONZA GROUP: BUSINESS OVERVIEW
FIGURE 39 LONZA GROUP: COMPANY SNAPSHOT
12.1.5 SARTORIUS AG
TABLE 194 SARTORIUS AG: BUSINESS OVERVIEW
FIGURE 40 SARTORIUS AG: COMPANY SNAPSHOT
12.1.6 TERUMO BCT, INC.
TABLE 195 TERUMO CORPORATION: BUSINESS OVERVIEW
FIGURE 41 TERUMO CORPORATION: COMPANY SNAPSHOT
12.1.7 BECTON, DICKINSON AND COMPANY
TABLE 196 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 42 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
12.1.8 FRESENIUS SE & CO. KGAA
TABLE 197 FRESENIUS SE & CO. KGAA: BUSINESS OVERVIEW
FIGURE 43 FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT
12.1.9 AVANTOR, INC.
TABLE 198 AVANTOR, INC.: BUSINESS OVERVIEW
FIGURE 44 AVANTOR, INC.: COMPANY SNAPSHOT
12.1.10 BIO-TECHNE CORPORATION
TABLE 199 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW
FIGURE 45 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT
12.1.11 CORNING INCORPORATED
TABLE 200 CORNING INCORPORATED: BUSINESS OVERVIEW
FIGURE 46 CORNING INCORPORATED: COMPANY SNAPSHOT
12.1.12 FUJIFILM IRVINE SCIENTIFIC
TABLE 201 FUJIFILM IRVINE SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 47 FUJIFILM IRVINE SCIENTIFIC: COMPANY SNAPSHOT
12.1.13 MAXCYTE, INC.
TABLE 202 MAXCYTE: BUSINESS OVERVIEW
FIGURE 48 MAXCYTE: COMPANY SNAPSHOT
*Details on Business Overview, Products Offered, Recent Developments, Deals, MnM view, Key strengths/right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS
12.2.1 WERUM IT SOLUTIONS
12.2.2 ROOSTERBIO, INC.
12.2.3 SIRION BIOTECH GMBH
12.2.4 TRAKCEL
12.2.5 L7 INFORMATICS
12.2.6 MILTENYI BIOTEC
12.2.7 STEMCELL TECHNOLOGIES INC.
12.2.8 GPI IBERIA (FORMERLY HEMASOFT)
12.2.9 MAK-SYSTEM
12.2.10 ORGANABIO, LLC
12.2.11 IXCELLS BIOTECHNOLOGIES
12.2.12 WILSON WOLF MANUFACTURING CORPORATION
13 APPENDIX (Page No. – 212)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
